Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Masanori Tsujie"'
Autor:
Kazuhiko Hashimoto, Yutaka Takeda, Hidenori Takahashi, Masahiro Murakami, Yongkook Kim, Shin Nakahira, Shogo Kobayashi, Keishi Sugimoto, Akira Tomokuni, Hirofumi Akita, Hidetoshi Eguchi, Junzo Shimizu, Naoki Hama, Tadafumi Asaoka, Masanori Tsujie, Shigekazu Yokoyama, Daisaku Yamada, Terumasa Yamada, Masahiro Tanemura, Osakuni Morimoto, Yuichiro Doki
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-11 (2021)
Trials
Trials
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To d
Autor:
Junzo Shimizu, Kazuhiko Hashimoto, Naoki Hama, Shogo Kobayashi, Hidetoshi Eguchi, Masanori Tsujie, Shigekazu Yokoyama, Osakuni Morimoto, Keishi Sugimoto, Akira Tomokuni, Yuichiro Doki, Terumasa Yamada, Yongkook Kim, Masahiro Tanemura, Yutaka Takeda, Masahiro Murakami, Daisaku Yamada, Shin Nakahira, Tadafumi Asaoka, Hirofumi Akita, Hidenori Takahashi
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::458167f78ca442636e33e1bf25b71b75
https://doi.org/10.21203/rs.3.rs-450436/v1
https://doi.org/10.21203/rs.3.rs-450436/v1
Autor:
Tomohisa Yamamoto, Hironaga Satake, Hiroaki Yanagimoto, Masanori Tsujie, Akihito Tsuji, Sohei Satoi, Masanori Toyoda, Hiroshi Wada, Hiroaki Nagano, Shigekazu Takemura, Kazuhiro Yanagihara, Atsushi Miyamoto, Hideyoshi Toyokawa, Tatsuya Ioka, Daisuke Sakai, Tetsuo Ajiki
Publikováno v:
Cancer chemotherapy and pharmacology. 81(3)
To determine the recommended dose (RD) of gemcitabine (GEM) plus S-1 (GS) in curatively resected biliary tract cancer (BTC) patients without major hepatectomy. A standard 3 + 3 dose-escalation design was used with planned dose levels (mg/m2) of GEM (
Autor:
Masanori Tsujie, Morito Monden, Masakazu Ikenaga, Kazumasa Fujitani, Masaki Kashiwazaki, Yutaka Takeda, Shoji Nakamori, Michihiko Miyazaki, Toshimasa Tsujinaka, Motohiro Hirao, Shin Nakahira, Hideyuki Mishima
Publikováno v:
Suizo. 22:21-25
膵癌に対する第1選択化学療法剤として広く使用されているgemcitabine(GEM)の作用機序解析に基づいた治療効果増強のための基礎的・臨床的検討を行った.ヒト膵癌細胞株およびヌードマ
Autor:
Keizo Dono, Shigeru Marubashi, Koji Umeshita, Masato Sakon, Shoji Nakamori, Masanori Tsujie, Ichiro Takemasa, Makoto Yamasaki, Jiro Okami, Atsushi Miyamoto, Hiroaki Nagano, Morito Monden, Yuji Takahashi, Yutaka Takeda, Shinichi Yoshioka, Shin Nakahira
Publikováno v:
International Journal of Cancer. 120:1355-1363
Pancreatic cancer is the most lethal of all solid tumors partially because of its chemoresistance. Although gemcitabine is widely used as a first selected agent for the treatment of this disease despite low response rate, molecular mechanisms of gemc
Autor:
Shin, Nakahira, Shoji, Nakamori, Masanori, Tsujie, Setsuo, Takeda, Keishi, Sugimoto, Yuji, Takahashi, Jiro, Okami, Shigeru, Marubashi, Atsushi, Miyamoto, Yutaka, Takeda, Hiroaki, Nagano, Keizo, Dono, Koji, Umeshita, Masato, Sakon, Morito, Monden
Publikováno v:
Anticancer research. 28(1A)
The systemic administration of gemcitabine (GEM) has been accepted as a standard treatment for patients with advanced pancreatic cancer. The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose ex
Autor:
Masanori, Tsujie, Shoji, Nakamori, Shin, Nakahira, Yuji, Takahashi, Nobuyasu, Hayashi, Jiro, Okami, Hiroaki, Nagano, Keizo, Dono, Koji, Umeshita, Masato, Sakon, Morito, Monden
Publikováno v:
Anticancer research. 27(4B)
The purpose of this study was to find a novel biomarker to predict 5-fluorouracil (5-FU) or gemcitabine (2',2'-difluoro-deoxycytidine) sensitivity in pancreatic cancer.The relationship between 5-FU and gemcitabine sensitivity and the mRNA levels of h
Autor:
Keizo Dono, Masato Sakon, Setsuo Takeda, Jiro Okami, Masanori Tsujie, Shoji Nakamori, Hiroaki Nagano, Morito Monden, Nobuyasu Hayashi, Shin Nakahira, Koji Umeshita, Yuji Takahashi
Publikováno v:
Pancreas. 33(2)
Objectives Gemcitabine is taken up by cells mainly via human equilibrative nucleoside transporter 1 (hENT1). Pretreatment of cancer cell lines with 5-fluorouracil (5-FU) leads to an increase in the expression of hENT1 and augments the effect of singl
Autor:
Masanori, Tsujie, Shoji, Nakamori, Shoichi, Nakazuru, Nobuyasu, Hayashi, Jiro, Okami, Hiroaki, Nagano, Keizo, Dono, Koji, Umeshita, Masato, Sakon, Morito, Monden
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 30(2)
We report a patient in whom systemic chemotherapy using gemcitabine was effective against liver metastases of pancreatic cancer. A 72-year-old woman underwent pancreatoduodenectomy with lymphadenectomy and partial resection of the portal vein followi
Autor:
Morito Monden, Masato Sakon, Jiro Okami, Shin Nakahira, Keizo Dono, Hiroaki Nagano, Masanori Tsujie, Yoshito Takeda, S. Nakamori, Ichiro Takemasa
Publikováno v:
Journal of Clinical Oncology. 24:4125-4125
4125 Background: Pancreatic cancer is the most lethal of all solid tumors partially because of its chemoresistance. Although a deoxycytidine analogue, gemcitabine, is widely used as a first selected and a single agent for the treatment of this diseas